Mentoring in patient-oriented atrial fibrillation and cardiovascular research

项目总结 此应用程序将为首席调查员Alvaro Alonso博士提供受保护的时间和其他支持 (1)促进指导初级临床研究人员和研究生的成功记录 以患者为中心的心血管研究；(2)获得组学、机器学习和 指导最佳实践；以及(3)推进阿隆索博士正在进行的风险因素和机制研究 有助于房颤(AF)的发展。指导活动将建立在正在进行的 阿隆索博士参与了埃默里大学的几个培训项目，包括由NHLBI资助的 关于心血管健康差异的多学科T32培训补助金，研究轨道心脏病学 医学院奖学金计划，公共卫生硕士和博士计划 罗林斯公共卫生学院的流行病学。培训将侧重于以下前沿方法领域 快速发展，包括以患者为中心的基因组技术和机器学习的整合 研究，以及在学术、研究和临床指导方面的技能获得。最后，这个奖项将 支持一个研究项目，该项目扩展了阿隆索博士正在进行的了解影响 房颤底物的发展，了解房颤的病理生理学，并预防房颤相关的结局。 本研究的具体目的是：(1)利用广泛的表型识别新的房颤表型 临床和多组学数据(“表观图谱”)，(2)发现不同房颤的特定危险因素 表型组，以及(3)确定房颤表型组与所选终点(中风、心脏)的关联 失败、死亡)。这些研究目标将在埃默里心血管生物库的背景下进行， 在埃默里附属的三家医院进行的一项正在进行的心脏导管术患者的前瞻性登记 医院目前包括大约7,000名具有详细表型、临床 结果，和多组标记。总而言之，本申请中提出的活动将产生积极的影响 阿隆索博士有能力进行以患者为导向的尖端和创新的心血管研究 预防以及他作为初级临床医生从事以下研究的高资质导师的能力 临床心血管流行病学和预防。

PROJECT SUMMARY This application will provide the Principal Investigator, Dr. Alvaro Alonso, with protected time and other support to (1) accelerate a successful record of mentoring junior clinical investigators and graduate students engaged in patient-oriented cardiovascular research; (2) obtain additional training in omics, machine learning, and mentoring best-practices; and (3) advance Dr. Alonso's ongoing research on the risk factors and mechanisms contributing to the development of atrial fibrillation (AF). Mentoring activities will build upon the ongoing involvement of Dr. Alonso in several training programs at Emory University, including an NHLBI-funded multidisciplinary T32 training grant on cardiovascular health disparities, the research-track Cardiology fellowship program at the School of Medicine, and the Master of Public Health and PhD programs in epidemiology at the Rollins School of Public Health. Training will focus on cutting-edge methodological areas in rapid development, including integration of omic technologies and machine learning in patient-oriented research, as well as acquisition of skills in academic, research, and clinical mentoring. Finally, this award will support a research project that extends Dr. Alonso's ongoing work on understanding the factors influencing the development of the AF substrate, understanding AF pathophysiology, and preventing AF-related outcomes. The specific aims of this research are: (1) to identify novel AF phenotypes (phenogroups) using extensive clinical and multi-omic data (“phenomapping”), (2) to discover specific risk factors for the different AF phenogroups, and (3) to determine associations of AF phenogroups with selected endpoints (stroke, heart failure, mortality). These research aims will be carried out in the context of the Emory Cardiovascular Biobank, an ongoing prospective registry of patients undergoing cardiac catheterization in three Emory-affiliated hospitals currently including approximately 7,000 unique individuals with detailed phenotyping, clinical outcomes, and multi-omic markers. In summary, the activities proposed in this application will favorably impact Dr. Alonso's capabilities to conduct cutting-edge and innovative patient-oriented research on cardiovascular prevention and his ability to perform as a highly qualified mentor for junior clinicians pursuing research on clinical cardiovascular epidemiology and prevention.